CGIX up +16.50% percent right now. $CGIX High is at 7.94

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 2:46 PM

CGIX up +16.50% percent right now. $CGIX High is at 7.94 and the Low 6.76 with current volume of 171,103.

Recent News posted below.

CGIX Cancer Genetics Inc Recent Headline News

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 45 mins ago

UCP: 11.90 (-1.89), JRJC: 6.24 (+0.73), NAVB: 1.03 (-0.19), SANW: 3.79 (+0.71), PLPM: 1.63 (+0.26), RYN: 28.80 (-5.10), INFU: 3.00 (-0.49), LIOX: 5.46 (+0.72), DY: 27.75 (-3.12), MTZ: 25.16 (-3.47), CGIX: 6.92 (+0.92), MUX: 1.25 (-0.16), OREX: 5.11 (+1.26), URRE: 2.59 (+0.65), ACHN: 12.56 (+2.45), REN: 2.83 (-0.78), MPO: 3.34 (+0.23), AKBA: 9.38 (-1.32), TRX: 1.02 (-0.20), PLNR: 7.53 (+1.13)

Cancer Genetics' (CGIX) CEO Panna Sharma on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - 2 hrs 17 mins ago

CGIX: 6.92 (+0.92)

Cancer Genetics ups revenues 88% in Q3
Seeking Alpha - at Seeking Alpha - 2 hrs 42 mins ago

CGIX: 6.92 (+0.92)

Cancer Genetics Announces Strong Third Quarter With Growth Across All Categories
GlobeNewswire - Mon Nov 10, 7:43AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the third quarter ended September 30, 2014.
CGIX: 6.92 (+0.92)

Cancer Genetics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:58AM CST

CGIX: 6.92 (+0.92)

Cancer Genetics, Inc. to Report Third Quarter 2014 Financial Results on Monday, November 10
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the third quarter financial results and to answer questions.
CGIX: 6.92 (+0.92)

Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers
GlobeNewswire - Tue Oct 21, 6:59AM CDT
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT(R))
CGIX: 6.92 (+0.92)

Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML
GlobeNewswire - Mon Oct 13, 6:45AM CDT
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CGIX: 6.92 (+0.92)

Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
PR Newswire - Thu Oct 09, 2:50PM CDT
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.
CGIX: 6.92 (+0.92)

Cancer Genetics Inc. to Provide Updates About the Company's Portfolio of Targeted Molecular Diagnostics at Analyst Day on September 25, 2014
GlobeNewswire - Wed Sep 24, 6:45AM CDT
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company"

, an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina.
CGIX: 6.92 (+0.92)

Cancer Genetics, Inc. and Beth Israel Deaconess Medical Center Enter Into Collaboration to Correlate Genomic Profiles to Patient Outcome in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Tue Sep 23, 6:45AM CDT
-- Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
CGIX: 6.92 (+0.92)

Cancer Genetics, Inc. to Present at Aegis Healthcare and Technology Conference on Thursday, September 11, 2014
GlobeNewswire - Wed Sep 10, 6:59AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT).
CGIX: 6.92 (+0.92)

Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
GlobeNewswire - Tue Sep 02, 7:15AM CDT
- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT(R)) has received the CE Marking.
CGIX: 6.92 (+0.92)

Cancer Genetics' Proprietary Genomic Diagnostic Tests Added to National Institutes of Health's Genetic Testing Registry
GlobeNewswire - Wed Aug 27, 6:59AM CDT
-- Online database allows clinicians and patients to search for genetic and genomic tests by disease state
CGIX: 6.92 (+0.92)

Cancer Genetics, Inc. and Leading Pathologist From Keck Medicine of USC Collaborate to Evaluate and Optimize Genomic Panel for Lymphoma
GlobeNewswire - Mon Aug 25, 7:30AM CDT
-- Collaboration will identify and evaluate new genomic markers for most common form of non-Hodgkin's lymphoma
CGIX: 6.92 (+0.92)

Cancer Genetics Inc. Completes Acquisition of BioServe India, a Premier Genomics and Next-Generation Sequencing Company
GlobeNewswire - Sun Aug 17, 11:00PM CDT
-- Cancer Genetics Now Positioned to Participate in High-Growth Indian Diagnostics Market, Where More Than 1 Million New Cancer Cases Are Diagnosed Each Year
CGIX: 6.92 (+0.92)

Cancer Genetics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 6:05AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial results for the second quarter and six months ended June 30, 2014.
CGIX: 6.92 (+0.92)

BioNano Genomics Announces The Purchase Of The Irys System By The Wellcome Trust Sanger Institute
PR Newswire - Tue Aug 12, 7:00AM CDT
BioNano Genomics announced today the purchase of an IrysTM System by the Wellcome Trust Sanger Institute, one of the world's leading genome centers, located near Cambridge, UK. The Sanger Institute made the largest single contribution to the gold standard sequence for the Human Genome Project and today is focused on the role of genetics in health and disease. The Sanger Institute purchased BioNano's Irys platform to detect structural variation and complete genomes for various projects including the Cancer Genomics Project, which seeks to develop new ways of detecting rearrangements in cancer samples, and the Parasite Genomics Team, which is sequencing the genomes of parasites that cause malaria and neglected tropical diseases prevalent in the developing world.
CGIX: 6.92 (+0.92)

Cancer Genetics to Report Second Quarter 2014 Financial Results on Thursday, August 14, 2014
GlobeNewswire - Fri Aug 08, 7:56AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report second quarter 2014 financial results on Thursday, August 14, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Time to discuss the second quarter financial results, the closing of the Gentris acquisition, the proposed FDA regulatory framework, and to answer questions.
CGIX: 6.92 (+0.92)

RedChip Issues Research Update on Cancer Genetics
GlobeNewswire - Thu Aug 07, 11:09AM CDT
RedChip Companies, Inc., today announced it has issued a research profile on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
CGIX: 6.92 (+0.92)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alaska Air Group's Q3: Facing Headwinds and Strategies

Weathering the Q3 Storm Alaska Air Group's third quarter results are in the bag, and let me tell ya, it's a mixed bag of sour lemons and hopeful limes. Reporting a net loss of $147 million or ($1.32) per share ain't the kind of results that plaster smiles on investors' faces. But hey, it's a volatile sector if there ever was one, especially with fuel costs ballooning to a...

University Highlights Scholars' Impact on Leadership

Navigating the Frontier of Academic Research There's a certain grit to diving headfirst into academia's tricky landscapes, and the University of Phoenix is throwing its cap in the ring with their inaugural President's Award. It's all happening at this virtual jamboree they call the Knowledge Without Boundaries Summit on October 22–23, 2026. They're spotlighting the...

Savarese Joins RID to Drive Diagnostic Innovation

A Seasoned Leader Bolsters RID's Ambitions Mario Savarese has joined Rapid Infection Diagnostics Inc.'s Strategic Advisory Board, and let me tell ya, this move's got potential. Appointing a heavyweight like Savarese as an advisor isn’t just a nod to his hefty resume. It’s about vaulting a burgeoning company into the big leagues. He's got over 20 years steering a ship...

India's Bharat RE 2026 Amidst Global Energy Stakes

India's Ambitious Energy Vision Diving right into it, India's ready to slap its mighty stamp on the global clean energy landscape. This grand affair, Bharat Renewable Energy Summit & Expo 2026, is calling in the big wigs from over 130 countries to New Delhi. It's not a casual gathering either—it's a serious play to crank up investment and tech alliances in renewable...

Valmet Fuels Century Sunshine's Pulp Revolution

Valmet's Bold Move in China's Pulp Industry Alright, let's dive deep into this pulp mill saga. Valmet isn't some novice in the industrial playing field, and their latest venture is a testament to that. They've clinched a hefty deal exceeding EUR 100 million to outfit Century Sunshine's Rizhao pulp mill in Shandong. This isn't just some small-time endeavor; it's a...

Ellevio Bolsters Stockholm Grid with SEK 1B NIB Loan

In a move that packs plenty of juice for Stockholm's energy needs, Ellevio has shaken hands with the Nordic Investment Bank (NIB) in a hefty SEK 1 billion loan agreement. This isn’t just some pocket change—this financing is a ticket to revamping and beefing up the Beckomberga substation, a project hailed for fortifying the regional electricity grid in the Swedish...

NEXT Properties' Exchange Offer Sees Strong Participation

NEXT Properties Makes Bold Moves with Exchange Offers NEXT Properties has pulled the trigger on a massive swap of its notes, and it's a tale investors should tune into. They're swapping out their old notes like a veteran trader ditching penny stocks for blue chips. It’s an intriguing maneuver—risk-laden yet foreboding to anyone who knows the game. Breaking Down the...

Orical's Big Win in Regulatory Reporting at US Awards

Orical Takes Home Prestigious Honor In the world of hedge funds, getting things straight with the regulators is as crucial as breathing. So, when Orical LLC snagged the "Regulatory Reporting Solution of the Year" at the Hedgeweek® US Awards 2026, it wasn't just a pat on the back. It screamed, "We've nailed this!" For a sector where compliance can feel like stepping...

DICK'S Sporting Goods Faces Legal Challenges in Securities Suit

Trouble Brewing at DICK'S Sporting Goods Wall Street's not only about the wins. There are moments when the market throws a curveball, and right now, DICK'S Sporting Goods is facing a fast one. DJS Law Group just laid out a class action lawsuit accusing them of bending the securities law rules. It ain't pretty when a company gets tangled up in legal battles, but it's...

Ballard Pushes Hydrogen-Powered Events to New Heights

Hydrogen Power Takes Center Stage Dive into the evolving world of event energy, and you'll find hydrogen right in the thick of things. This summer, Ballard and newly acquired GeoPura made a splash by marrying hydrogen power with live entertainment, thanks to fuel cells that kept the lights on and the amps buzzing without spewing pollutants. Cultural and Sporting Arenas...